Qiagen : Q1 2022 results release and guidance uplift an early, positive surprise
>Q1 a clear beat thanks to coronavirus-related revenues - Qiagen reported Q1 results one day ahead of schedule. Q1 was even stronger than we had estimated with sales ($ 628m) some 5% ahead of our forecast ($ 599m) and 6% ahead of consensus ($ 590). FX headwinds (the company reports in $) were -4%, in line with our forecast. Hence, underlying performance was strong at +15% y-o-y vs +10% y-o-y we estimated. While non-Covid related sales of $ 400m were about in line with...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.